In summary, IFI16 exerts its effects by modulating IL6, which activates the IL6/PI3K/AKT pathway, promoting the occurrence of ccRCC EMT, and ultimately enhancing tumor proliferation and metastasis (Fig. 9F). The gene discussed is AKT1; the disease is nonpapillary renal cell carcinoma.